KR850000301B1 - 페닐에탄올 아민 유도체의 제조 방법 - Google Patents
페닐에탄올 아민 유도체의 제조 방법 Download PDFInfo
- Publication number
- KR850000301B1 KR850000301B1 KR1019810002490A KR810002490A KR850000301B1 KR 850000301 B1 KR850000301 B1 KR 850000301B1 KR 1019810002490 A KR1019810002490 A KR 1019810002490A KR 810002490 A KR810002490 A KR 810002490A KR 850000301 B1 KR850000301 B1 KR 850000301B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- terbutalin
- bronchial
- nmr
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 13
- 150000001412 amines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 99
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 41
- 229960000195 terbutaline Drugs 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- 230000001773 anti-convulsant effect Effects 0.000 description 17
- 229960004132 diethyl ether Drugs 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 11
- 239000001961 anticonvulsive agent Substances 0.000 description 11
- 229960003965 antiepileptics Drugs 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- -1 bitolterol compound Chemical class 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000003182 bronchodilatating effect Effects 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PTZIWUJNBZOUQD-UHFFFAOYSA-N [3-(2-bromoacetyl)phenyl] n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=CC(C(=O)CBr)=C1 PTZIWUJNBZOUQD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- 230000002082 anti-convulsion Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- DLSOILHAKCBARI-UHFFFAOYSA-N n-benzyl-2-methylpropan-2-amine Chemical compound CC(C)(C)NCC1=CC=CC=C1 DLSOILHAKCBARI-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229960002052 salbutamol Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- WQXWIKCZNIGMAP-UHFFFAOYSA-N 3',5'-Dihydroxyacetophenone Chemical compound CC(=O)C1=CC(O)=CC(O)=C1 WQXWIKCZNIGMAP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 0 CC[C@](CC(C1)C(*)=O)(CC1O*(C)c1ccccc1)OI=[O+] Chemical compound CC[C@](CC(C1)C(*)=O)(CC1O*(C)c1ccccc1)OI=[O+] 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- MHSCTPSUPCVLAG-UHFFFAOYSA-N [3-(2-bromoacetyl)-5-(ethylcarbamoyloxy)phenyl] n-ethylcarbamate Chemical compound CCNC(=O)OC1=CC(OC(=O)NCC)=CC(C(=O)CBr)=C1 MHSCTPSUPCVLAG-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229960004620 bitolterol Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002329 esterase inhibitor Substances 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- MMNNFMKNCOKXLZ-UHFFFAOYSA-N n-benzyl-2-methylpropan-2-amine;hydrobromide Chemical compound Br.CC(C)(C)NCC1=CC=CC=C1 MMNNFMKNCOKXLZ-UHFFFAOYSA-N 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- RGURBRHZWFDJBM-UHFFFAOYSA-N C=CCC1C=CCCC1 Chemical compound C=CCC1C=CCCC1 RGURBRHZWFDJBM-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- UBNDVPXMXCAYSA-UHFFFAOYSA-N [3-(2-bromoacetyl)-5-phenylmethoxyphenyl] n,n-dimethylcarbamate Chemical compound BrCC(=O)C1=CC(OC(=O)N(C)C)=CC(OCC=2C=CC=CC=2)=C1 UBNDVPXMXCAYSA-UHFFFAOYSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229950002451 ibuterol Drugs 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003189 isokinetic effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- AMSQLGKJQMTZNO-UHFFFAOYSA-N n-benzyl-1-methylcyclobutan-1-amine Chemical compound C=1C=CC=CC=1CNC1(C)CCC1 AMSQLGKJQMTZNO-UHFFFAOYSA-N 0.000 description 1
- KCAPTTPXCZRLTD-UHFFFAOYSA-N n-benzylcyclobutanamine Chemical compound C=1C=CC=CC=1CNC1CCC1 KCAPTTPXCZRLTD-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/34—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton and at least one hydroxy group bound to another carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Luminescent Compositions (AREA)
- Saccharide Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019840005925A KR850000871B1 (ko) | 1980-07-09 | 1984-09-26 | 페닐에탄올아민 유도체의 제조방법 |
| KR1019840005924A KR850000870B1 (ko) | 1980-07-09 | 1984-09-26 | 페닐에탄올아민 유도체의 제조방법 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8022439 | 1980-07-09 | ||
| GB8022439 | 1980-07-09 | ||
| GB8116441 | 1981-05-29 | ||
| GB8116,441 | 1981-05-29 | ||
| GB8116441 | 1981-05-29 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019840005924A Division KR850000870B1 (ko) | 1980-07-09 | 1984-09-26 | 페닐에탄올아민 유도체의 제조방법 |
| KR1019840005925A Division KR850000871B1 (ko) | 1980-07-09 | 1984-09-26 | 페닐에탄올아민 유도체의 제조방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR830006174A KR830006174A (ko) | 1983-09-20 |
| KR850000301B1 true KR850000301B1 (ko) | 1985-03-18 |
Family
ID=26276161
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019810002490A Expired KR850000301B1 (ko) | 1980-07-09 | 1981-07-09 | 페닐에탄올 아민 유도체의 제조 방법 |
| KR1019840005925A Expired KR850000871B1 (ko) | 1980-07-09 | 1984-09-26 | 페닐에탄올아민 유도체의 제조방법 |
| KR1019840005924A Expired KR850000870B1 (ko) | 1980-07-09 | 1984-09-26 | 페닐에탄올아민 유도체의 제조방법 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019840005925A Expired KR850000871B1 (ko) | 1980-07-09 | 1984-09-26 | 페닐에탄올아민 유도체의 제조방법 |
| KR1019840005924A Expired KR850000870B1 (ko) | 1980-07-09 | 1984-09-26 | 페닐에탄올아민 유도체의 제조방법 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US4419364A (https=) |
| EP (1) | EP0043807B1 (https=) |
| KR (3) | KR850000301B1 (https=) |
| AT (1) | ATE7689T1 (https=) |
| AU (1) | AU539976B2 (https=) |
| CA (1) | CA1180021A (https=) |
| CS (1) | CS221845B2 (https=) |
| CY (1) | CY1273A (https=) |
| DD (1) | DD202001A5 (https=) |
| DE (1) | DE3163871D1 (https=) |
| DK (1) | DK157678C (https=) |
| ES (3) | ES8300678A1 (https=) |
| FI (1) | FI73666C (https=) |
| GR (1) | GR74291B (https=) |
| HK (1) | HK5385A (https=) |
| HU (2) | HU184959B (https=) |
| IE (1) | IE51373B1 (https=) |
| IS (1) | IS1262B6 (https=) |
| LU (1) | LU88304I2 (https=) |
| MX (1) | MX9203239A (https=) |
| MY (1) | MY8700026A (https=) |
| NO (2) | NO152130C (https=) |
| NZ (1) | NZ197628A (https=) |
| PH (2) | PH16535A (https=) |
| PL (1) | PL128513B1 (https=) |
| PT (1) | PT73336B (https=) |
| SG (1) | SG79784G (https=) |
| SU (1) | SU1128830A3 (https=) |
| YU (3) | YU42116B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904064D0 (sv) * | 1989-12-01 | 1989-12-01 | Astra Ab | Improved method of preparing an intermediate for the manufacture of bambuterol |
| SE9000948D0 (sv) * | 1990-03-16 | 1990-03-16 | Draco Ab | New use |
| US5830422A (en) * | 1995-06-23 | 1998-11-03 | Ormiston Mining And Smelting Co. Ltd. | Method for production of sodium bicarbonate, sodium carbonate and ammonium sulfate from sodium sulfate |
| CA2247953A1 (en) * | 1996-01-29 | 1997-07-31 | E. Charles Pesterfield Jr. | Method of treating undesired uterine contractions using optically pure r- or rr-isomers of adrenergic beta-2 agonists |
| SE9604752D0 (sv) * | 1996-12-20 | 1996-12-20 | Astra Ab | Formulation and use |
| KR20030085658A (ko) * | 2002-04-30 | 2003-11-07 | 한올제약주식회사 | 밤부테롤의 개선된 합성방법 |
| WO2004014290A2 (en) * | 2002-08-08 | 2004-02-19 | Cheng J L | R-bambuterol, its preparation and therapeutic uses |
| US7495028B2 (en) * | 2002-08-08 | 2009-02-24 | Wen Tan | R-bambuterol, its preparation and therapeutic uses |
| JP2007504123A (ja) * | 2003-08-29 | 2007-03-01 | ランバクシー ラボラトリーズ リミテッド | Ｉｖ型ホスホジエステラーゼの阻害剤 |
| EP1694655A2 (en) * | 2003-11-26 | 2006-08-30 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
| WO2006081986A1 (en) * | 2005-02-07 | 2006-08-10 | F.Hoffmann-La Roche Ag | Bambuterol and integrin inhibitor combination |
| WO2007031838A1 (en) | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| WO2007045980A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type iv inhibitors |
| RU2008119323A (ru) | 2005-10-19 | 2009-11-27 | Рэнбакси Лабораториз Лимитед (In) | Фармацевтические композиции мускаринового рецептора |
| ES2397284T3 (es) | 2006-08-22 | 2013-03-06 | Ranbaxy Laboratories Limited | Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos |
| EA200900472A1 (ru) * | 2006-09-22 | 2009-10-30 | Ранбакси Лабораторис Лимитед | Ингибиторы фосфодиэстеразы iv типа |
| US20100029728A1 (en) * | 2006-09-22 | 2010-02-04 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
| EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
| WO2008111009A1 (en) * | 2007-03-14 | 2008-09-18 | Ranbaxy Laboratories Limited | Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors |
| DK2124944T3 (da) | 2007-03-14 | 2012-04-23 | Ranbaxy Lab Ltd | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer |
| EP2111861A1 (en) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
| SG187654A1 (en) | 2010-07-30 | 2013-03-28 | Ranbaxy Lab Ltd | Matrix metalloproteinase inhibitors |
| CA2812319A1 (en) | 2010-09-24 | 2012-03-29 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
| MX368898B (es) | 2012-12-03 | 2019-10-21 | Pfizer | Moduladores selectivos del receptor de androgenos novedosos. |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| CN104557614B (zh) * | 2014-12-15 | 2017-01-04 | 广东东阳光药业有限公司 | 一种胺的还原方法 |
| CN105622461B (zh) * | 2016-01-29 | 2018-06-19 | 华南理工大学 | 一种化合物及其制备方法与应用 |
| CN105859589B (zh) * | 2016-04-05 | 2018-09-28 | 深圳市康立生生物科技有限公司 | 一种制备班布特罗杂质c的方法 |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| CN109942462B (zh) * | 2019-03-06 | 2022-01-14 | 宏冠生物药业有限公司 | 一种盐酸班布特罗的合成工艺 |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| CN117586152B (zh) * | 2023-11-23 | 2026-04-03 | 黑龙江乌苏里江制药有限公司 | 一种盐酸班布特罗的制备方法 |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
| CN120585720A (zh) * | 2025-06-12 | 2025-09-05 | 肇庆学院 | 一种双靶点药物的经鼻给药制剂及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE178032C1 (https=) | 1961-01-01 | |||
| DE1643488U (de) | 1949-11-28 | 1952-09-11 | G E Hilge Fa | Brutgeraet. |
| DK85789C (da) | 1955-07-05 | 1958-06-30 | Cilag Ag | Fremgangsmåde til fremstilling af d,1- eller 1-isopropyl-aminometyl-(3,4-dihydroksy-fenyl)-karbinol eller salte deraf. |
| DE1768167U (de) | 1958-04-02 | 1958-06-04 | Artur O Herrmann | Warngeraet bei strassenhindernissen. |
| DE1275069B (de) | 1960-02-15 | 1968-08-14 | Boehringer Sohn Ingelheim | 1-(3', 5'-Dihydroxyphenyl)-1-hydroxy-2-isopropylaminoalkane und Verfahren zu ihrer Herstellung |
| BE622434A (https=) | 1961-09-14 | |||
| FR1324857A (fr) * | 1962-06-14 | 1963-04-19 | Chemie Linz Ag | Procédé pour la préparation de dérivés de la phényléthanolamine |
| GB1141606A (en) | 1965-04-12 | 1969-01-29 | Rech S Et D Applic Scient Et M | Improvements in alkyl ethers of substituted phenylaminoethanols |
| DE1543372A1 (de) | 1966-10-18 | 1971-04-01 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von o-substituierten 3,4-Dioxyphenylalkanolaminen |
| US3937838A (en) * | 1966-10-19 | 1976-02-10 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds and their preparation |
| SE335359B (https=) | 1966-10-19 | 1971-05-24 | Draco Ab | |
| NO132866C (https=) | 1966-10-19 | 1976-01-21 | Draco Ab | |
| SE358633B (https=) | 1966-10-19 | 1973-08-06 | Draco Ab | |
| FR6087M (https=) | 1967-01-10 | 1968-06-04 | ||
| SE369299B (https=) | 1967-10-18 | 1974-08-19 | Draco Ab | |
| SE338324B (https=) | 1967-12-19 | 1971-09-06 | Haessle Ab | |
| NO129903B (https=) | 1969-04-01 | 1974-06-10 | Sterling Drug Inc | |
| AT294046B (de) | 1969-07-08 | 1971-11-10 | Chemie Linz Ag | Verfahren zur Herstellung des N,N'-Bis[2-(3',4'-dihydroxyphenyl)-2-hydroxyäthyl]-hexamethylendiamins, seiner optisch aktiven Formen und der Salze derselben |
| US3657319A (en) * | 1970-05-05 | 1972-04-18 | Smith Kline French Lab | Alpha-aminoalkyl-4-hydroxy-3-carboalkoxyaminobenzyl alcohols |
| NO126437B (https=) | 1970-08-05 | 1973-02-05 | Draco Ab | |
| NL7112938A (https=) | 1970-09-30 | 1972-04-05 | ||
| CH550771A (de) | 1970-10-30 | 1974-06-28 | Hoffmann La Roche | Verfahren zur herstellung von phenaethylaminderivaten. |
| US3876679A (en) | 1970-12-09 | 1975-04-08 | Aldrich Chem Co Inc | Di-substituted phenethylcarbamic acid esters |
| FI55988C (fi) | 1971-10-19 | 1979-11-12 | Klinge Co Chem Pharm Fab | Foerfarande foer framstaellning av terapeutiskt anvaendbara o-acylfenoletanolaminer |
| US4011258A (en) | 1973-06-21 | 1977-03-08 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds |
| FI56673C (fi) | 1974-03-29 | 1981-02-04 | Huhtamaeki Yhthymae Oy | Nytt foerfarande foer framstaellning av alfa-tert-bytylaminometyl-4-hydroxy-m-xylen-alfa1 alfa3-diol |
| JPS556625B2 (https=) * | 1974-05-16 | 1980-02-18 | ||
| US4063025A (en) * | 1975-02-05 | 1977-12-13 | Yamanouchi Pharmaceutical Co., Ltd. | 4-Substituted amino-α-aminomethylbenzyl alcohol derivatives |
| SE7510988L (sv) | 1975-10-01 | 1977-04-02 | Draco Ab | Nya farmaceutiskt aktiva foreningar |
| DE2710997C3 (de) * | 1977-03-14 | 1980-08-14 | Dr. Karl Thomae Gmbh, 7950 Biberach | 4-Alkoxy carbonylamino-phenyläthanolamine, deren Herstellung und deren Verwendung als Arzneimittel |
-
1981
- 1981-06-30 DE DE8181850117T patent/DE3163871D1/de not_active Expired
- 1981-06-30 AT AT81850117T patent/ATE7689T1/de active
- 1981-06-30 EP EP81850117A patent/EP0043807B1/en not_active Expired
- 1981-06-30 CY CY1273A patent/CY1273A/xx unknown
- 1981-07-01 US US06/279,672 patent/US4419364A/en not_active Expired - Lifetime
- 1981-07-07 NO NO812311A patent/NO152130C/no unknown
- 1981-07-07 NZ NZ197628A patent/NZ197628A/en unknown
- 1981-07-07 PH PH25872A patent/PH16535A/en unknown
- 1981-07-07 AU AU72618/81A patent/AU539976B2/en not_active Expired
- 1981-07-07 IE IE1522/81A patent/IE51373B1/en not_active IP Right Cessation
- 1981-07-08 CA CA000381360A patent/CA1180021A/en not_active Expired
- 1981-07-08 CS CS815265A patent/CS221845B2/cs unknown
- 1981-07-08 ES ES503768A patent/ES8300678A1/es not_active Expired
- 1981-07-08 PL PL1981232108A patent/PL128513B1/pl unknown
- 1981-07-08 FI FI812158A patent/FI73666C/fi not_active IP Right Cessation
- 1981-07-08 SU SU813308249A patent/SU1128830A3/ru active
- 1981-07-08 DK DK303481A patent/DK157678C/da active
- 1981-07-08 PT PT73336A patent/PT73336B/pt unknown
- 1981-07-08 HU HU811986A patent/HU184959B/hu unknown
- 1981-07-08 IS IS2657A patent/IS1262B6/is unknown
- 1981-07-08 HU HU813788A patent/HU187611B/hu unknown
- 1981-07-09 GR GR65453A patent/GR74291B/el unknown
- 1981-07-09 KR KR1019810002490A patent/KR850000301B1/ko not_active Expired
- 1981-07-09 YU YU1704/81A patent/YU42116B/xx unknown
- 1981-07-09 DD DD81231626A patent/DD202001A5/de unknown
-
1982
- 1982-06-15 ES ES513109A patent/ES8304534A1/es not_active Expired
- 1982-06-15 ES ES513108A patent/ES513108A0/es active Granted
- 1982-07-06 US US06/395,650 patent/US4451663A/en not_active Expired - Lifetime
- 1982-07-23 PH PH27617A patent/PH19447A/en unknown
-
1983
- 1983-04-15 YU YU863/83A patent/YU43168B/xx unknown
- 1983-04-15 YU YU864/83A patent/YU43169B/xx unknown
-
1984
- 1984-09-26 KR KR1019840005925A patent/KR850000871B1/ko not_active Expired
- 1984-09-26 KR KR1019840005924A patent/KR850000870B1/ko not_active Expired
- 1984-11-09 SG SG797/84A patent/SG79784G/en unknown
-
1985
- 1985-01-17 HK HK53/85A patent/HK5385A/en not_active IP Right Cessation
-
1987
- 1987-12-30 MY MY26/87A patent/MY8700026A/xx unknown
-
1992
- 1992-06-24 MX MX9203239A patent/MX9203239A/es unknown
-
1993
- 1993-06-16 LU LU88304C patent/LU88304I2/fr unknown
-
1996
- 1996-06-27 NO NO1996008C patent/NO1996008I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR850000301B1 (ko) | 페닐에탄올 아민 유도체의 제조 방법 | |
| US3705233A (en) | Phenylaminoethanol derivatives | |
| US4011258A (en) | Orally active bronchospasmolytic compounds | |
| US3937838A (en) | Orally active bronchospasmolytic compounds and their preparation | |
| EP0031104B1 (en) | Thiazolidine compounds, processes for their preparation and pharmaceutical compositions containing them | |
| KR0165131B1 (ko) | 1,4-벤조티아제핀 유도체 | |
| DK169337B1 (da) | Xanthinforbindelser, farmaceutisk præparat indeholdende disse, xanthinforbindelser til anvendelse som et farmaceutisk middel samt fremgangsmåde til fremstilling af forbindelserne | |
| JPH07223953A (ja) | 中枢神経系疾患治療用薬剤組成物 | |
| KR0139626B1 (ko) | 강심제 | |
| EP0089028B1 (de) | Neue Theophyllin-Derivate und Verfahren zu ihrer Herstellung | |
| EP2002831A1 (en) | R-Bambuterol, its preparation and therapeutic uses | |
| JPH03504123A (ja) | １、３―チアゾリジンのβ―カルボニルカルボキシアミド | |
| US4528299A (en) | 1-(2,3-Dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1-propanone and anti-spastic use thereof | |
| US4442300A (en) | Therapeutically active compounds | |
| JPS5935387B2 (ja) | ３−アミノ−２−ヒドロキシプロパンのジ−置換フエノ−ルエ−テル類、その製法ならびに医薬用途 | |
| US7495028B2 (en) | R-bambuterol, its preparation and therapeutic uses | |
| JPH0226628B2 (https=) | ||
| SI8111704A8 (sl) | Postopek za pripravo etanolaminskih derivatov | |
| JPH1059950A (ja) | ５−フェニル−３−ピリダジノン誘導体 | |
| KR890000619B1 (ko) | 1-아릴옥시-3-알키닐아미노-프로판-2-올의 제조방법 | |
| CS228126B2 (cs) | Způsob výroby nových derivátů l-(4-hydroxyfenyl)-2-aminoethanolu | |
| JPH0374234B2 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19810709 |
|
| PG1501 | Laying open of application | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19840428 Patent event code: PE09021S01D |
|
| PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19850208 |
|
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19850605 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19850613 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19850613 End annual number: 3 Start annual number: 1 |
|
| PR1001 | Payment of annual fee |
Payment date: 19880211 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 19890303 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 19900222 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 19910315 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 19920314 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 19930312 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 19940314 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 19950310 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 19960306 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 19970311 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 19971224 Start annual number: 14 End annual number: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 19990213 Start annual number: 15 End annual number: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 19991229 Start annual number: 16 End annual number: 16 |
|
| PR1001 | Payment of annual fee |
Payment date: 20010111 Start annual number: 17 End annual number: 17 |
|
| PC1801 | Expiration of term |